Advertisement

Impact of Periprocedural Atrial Fibrillation on Short-Term Clinical Outcomes Following Percutaneous Coronary Intervention

Published:December 19, 2011DOI:https://doi.org/10.1016/j.amjcard.2011.10.004
      There are few data on the incidence and clinical outcomes of patients with atrial fibrillation (AF) treated in the era of percutaneous coronary intervention (PCI). We analyzed 30-day clinical outcomes in 3,307 consecutive patients with and without AF (sinus rhythm) undergoing PCI from January 2007 through December 2008 enrolled in a multicenter Australian registry. Periprocedural AF was present in 162 patients (4.9%). AF was associated with older age (74.1 ± 8.9 vs 63.9 ± 11.9 years, p <0.001), higher baseline serum creatinine (0.13 ± 0.14 vs 0.10 ± 0.13 mmol/L, p = 0.01), and lower left ventricular ejection fraction (49.5 ± 13.2% vs 53.4% ± 11.6%, p <0.001). Significantly more patients with AF had a history of heart failure and cerebrovascular and peripheral arterial diseases (p ≤0.01 for all comparisons). Periprocedural glycoprotein IIb/IIIa inhibitor (31.5% vs 31.4%, p = 0.98) and antithrombin use were not different between groups, but in-hospital bleeding complications were higher in patients with AF (5.0% vs 2.1%, p = 0.015). Fewer patients with AF received drug-eluting stents (p = 0.004). AF was associated with a greater than fourfold increase in 30-day mortality (9.9% vs 2.2%, p <0.0001) and readmission rates at 30 days (p = 0.01). Fewer patients with AF were on dual antiplatelet therapy at 30 days (86.3% vs 94.3%, p <0.0001), although 28.1% of patients with AF were on triple therapy (dual antiplatelet therapy plus oral anticoagulation). In conclusion, patients with periprocedural AF represent a very high-risk group. Excess 30-day morbidity and mortality after PCI may be due to the higher incidence of co-morbidities, bleeding complications, and suboptimal antiplatelet therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lopes R.D.
        • Pieper K.S.
        • Horton J.R.
        • Al-Khatib S.M.
        • Newby L.K.
        • Mehta R.H.
        • Van de Werf F.
        • Armstrong P.W.
        • Mahaffey K.W.
        • Harrington R.A.
        • Ohman E.M.
        • White H.D.
        • Wallentin L.
        • Granger C.B.
        Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation.
        Heart. 2008; 94: 867-873
        • Kinjo K.
        • Sato H.
        • Ohnishi Y.
        • Hishida E.
        • Nakatani D.
        • Mizuno H.
        • Fukunami M.
        • Koretsune Y.
        • Takeda H.
        • Hori M.
        Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention.
        Am J Cardiol. 2003; 92: 1150-1154
        • El-Omar M.M.
        • Dangas G.
        • Mehran R.
        • Lansky A.J.
        • Kipshidze N.N.
        • Polena S.
        • Fahy M.
        • Moussa I.
        • Glasser L.
        • Moses J.W.
        • Stone G.W.
        • Leon M.B.
        Usefulness of atrial fibrillation as a marker of outcome after percutaneous coronary intervention.
        Am J Cardiol. 2003; 91: 232-234
        • Ruiz-Nodar J.M.
        • Marín F.
        • Hurtado J.A.
        • Valencia J.
        • Pinar E.
        • Pineda J.
        • Gimeno J.R.
        • Sogorb F.
        • Valdés M.
        • Lip G.Y.
        Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis.
        J Am Coll Cardiol. 2008; 51: 818-825
        • Ajani A.E.
        • Szto G.
        • Duffy S.J.
        • Eccleston D.
        • Clark D.J.
        • Lefkovits J.
        • Chew D.P.
        • Warren R.
        • Black A.
        • New G.
        • Walton A.
        • Lew R.
        • Shaw J.
        • Horrigan M.
        • Sebastian M.
        • Yan B.P.
        • Brennan A.
        • Meehan A.
        • Reid C.
        • Krum H.
        • Melbourne Interventional Group investigators
        The foundation and launch of the Melbourne Interventional Group: a collaborative interventional cardiology project.
        Heart Lung Circ. 2006; 15: 44-47
        • Lagerqvist B.
        • James S.K.
        • Stenestrand U.
        • Lindbäck J.
        • Nilsson T.
        • Wallentin L.
        • SCAAR Study Group
        Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.
        N Engl J Med. 2007; 356: 1009-1019
        • Butler M.J.
        • Eccleston D.
        • Clark D.J.
        • Ajani A.E.
        • Andrianopoulos N.
        • Brennan A.
        • New G.
        • Black A.
        • Szto G.
        • Reid C.M.
        • Yan B.P.
        • Shaw J.A.
        • Dart A.M.
        • Duffy S.J.
        • Melbourne Interventional Group
        The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents.
        Am Heart J. 2009; 157: 899-907
        • Behar S.
        • Zahavi Z.
        • Goldbourt U.
        • Reicher-Reiss H.
        Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction.
        Eur Heart J. 1992; 13: 45-50
        • Crenshaw B.S.
        • Ward S.R.
        • Granger C.B.
        • Stebbins A.L.
        • Topol E.J.
        • Califf R.M.
        Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience.
        J Am Coll Cardiol. 1997; 30: 406-413
        • Pizzetti F.
        • Turazza F.M.
        • Franzosi M.G.
        • Barlera S.
        • Ledda A.
        • Maggioni A.P.
        • Santoro L.
        • Tognoni G.
        • GISSI-3 Investigators
        Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data.
        Heart. 2001; 86: 527-532
        • Manzano-Fernández S.
        • Pastor F.J.
        • Marín F.
        • Cambronero F.
        • Caro C.
        • Pascual-Figal D.A.
        • Garrido I.P.
        • Pinar E.
        • Valdés M.
        • Lip G.Y.
        Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
        Chest. 2008; 134: 559-567
        • Marte T.
        • Saely C.H.
        • Schmid F.
        • Koch L.
        • Drexel H.
        Effectiveness of atrial fibrillation as an independent predictor of death and coronary events in patients having coronary angiography.
        Am J Cardiol. 2009; 103: 36-40
        • Ruiz-Nodar J.M.
        • Marín F.
        • Sánchez-Payá J.
        • Hurtado J.A.
        • Valencia-Martín J.
        • Manzano-Fernández S.
        • Roldán V.
        • Pérez-Andreu V.
        • Sogorb F.
        • Valdés M.
        • Lip G.Y.
        Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation.
        Eur Heart J. 2009; 30: 932-939
        • Manoukian S.V.
        • Feit F.
        • Mehran R.
        • Voeltz M.D.
        • Ebrahimi R.
        • Hamon M.
        • Dangas G.D.
        • Lincoff A.M.
        • White H.D.
        • Moses J.W.
        • King III, S.B.
        • Ohman E.M.
        • Stone G.W.
        Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.
        J Am Coll Cardiol. 2007; 49: 1362-1368
        • Mehran R.
        • Lansky A.J.
        • Witzenbichler B.
        • Guagliumi G.
        • Peruga J.Z.
        • Brodie B.R.
        • Dudek D.
        • Kornowski R.
        • Hartmann F.
        • Gersh B.J.
        • Pocock S.J.
        • Wong S.C.
        • Nikolsky E.
        • Gambone L.
        • Vandertie L.
        • Parise H.
        • Dangas G.D.
        • Stone G.W.
        • HORIZONS-AMI Trial Investigators
        Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
        Lancet. 2009; 374: 1149-1159
        • Orford J.L.
        • Fasseas P.
        • Melby S.
        • Burger K.
        • Steinhubl S.R.
        • Holmes D.R.
        • Berger P.B.
        Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
        Am Heart J. 2004; 147: 463-467
        • Karjalainen P.P.
        • Porela P.
        • Ylitalo A.
        • Vikman S.
        • Nyman K.
        • Vaittinen M.A.
        • Airaksinen T.J.
        • Niemelä M.
        • Vahlberg T.
        • Airaksinen K.E.
        Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting.
        Eur Heart J. 2007; 28: 726-732
        • Rogacka R.
        • Chieffo A.
        • Michev I.
        • Airoldi F.
        • Latib A.
        • Cosgrave J.
        • Montorfano M.
        • Carlino M.
        • Sangiorgi G.M.
        • Castelli A.
        • Godino C.
        • Magni V.
        • Aranzulla T.C.
        • Romagnoli E.
        • Colombo A.
        Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation.
        JACC Cardiovasc Interv. 2008; 1: 56-61
        • Khurram Z.
        • Chou E.
        • Minutello R.
        • Bergman G.
        • Parikh M.
        • Naidu S.
        • Wong S.C.
        • Hong M.K.
        Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
        J Invasive Cardiol. 2006; 18: 162-164
        • Paikin J.S.
        • Wright D.S.
        • Crowther M.A.
        • Mehta S.R.
        • Eikelboom J.W.
        Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents.
        Circulation. 2010; 121: 2067-2070
        • Lip G.Y.
        • Huber K.
        • Andreotti F.
        • Arnesen H.
        • Airaksinen J.K.
        • Cuisset T.
        • Kirchhof P.
        • Marín F.
        • Consensus Document of European Society of Cardiology Working Group on Thrombosis
        Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
        Eur Heart J. 2010; 31: 1311-1318
        • Aggarwal A.
        • Dai D.
        • Rumsfeld J.S.
        • Klein L.W.
        • Roe M.T.
        Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention.
        Am J Cardiol. 2008; 101: 1413-1417
        • Porter A.
        • Konstantino Y.
        • Iakobishvili Z.
        • Shachar L.
        • Battler A.
        • Hasdai D.
        Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention.
        Catheter Cardiovasc Interv. 2006; 68: 56-61
        • Buresly K.
        • Eisenberg M.J.
        • Zhang X.
        • Pilote L.
        Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
        Arch Intern Med. 2005; 165: 784-789
        • Silber S.
        • Albertsson P.
        • Avilés F.F.
        • Camici P.G.
        • Colombo A.
        • Hamm C.
        • Jørgensen E.
        • Marco J.
        • Nordrehaug J.E.
        • Ruzyllo W.
        • Urban P.
        • Stone G.W.
        • Wijns W.
        • Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
        Guidelines for percutaneous coronary interventions.
        Eur Heart J. 2005; 26: 804-847
        • Smith Jr, S.C.
        • Feldman T.E.
        • Hirshfeld Jr, J.W.
        • Jacobs A.K.
        • Kern M.J.
        • King III, S.B.
        • Morrison D.A.
        • O'Neil W.W.
        • Schaff H.V.
        • Whitlow P.L.
        • Williams D.O.
        • Antman E.M.
        • Adams C.D.
        • Anderson J.L.
        • Faxon D.P.
        • Fuster V.
        • Halperin J.L.
        • Hiratzka L.F.
        • Hunt S.A.
        • Nishimura R.
        • Ornato J.P.
        • Page R.L.
        • Riegel B.
        ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).
        Circulation. 2006; 113: e166-e286
        • Fuster V.
        • Ryden L.E.
        • Cannom D.S.
        • Crijns H.J.
        • Curtis A.B.
        • Ellenbogen K.A.
        • Halperin J.L.
        • Le Heuzey J.Y.
        • Kay G.N.
        • Lowe J.E.
        • Olsson S.B.
        • Prystowsky E.N.
        • Tamargo J.L.
        • Wann S.
        ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation).
        Eur Heart J. 2006; 27: 1979-2030
        • Nguyen M.C.
        • Lim Y.L.
        • Walton A.
        • Lefkovits J.
        • Agnelli G.
        • Goodman S.G.
        • Budaj A.
        • Gulba D.C.
        • Allegrone J.
        • Brieger D.
        • GRACE Investigators
        Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?.
        Eur Heart J. 2007; 28: 1717-1722
        • Rubboli A.
        • Halperin J.L.
        • Airaksinen K.E.
        • Buerke M.
        • Eeckhout E.
        • Freedman S.B.
        • Gershlick A.H.
        • Schlitt A.
        • Tse H.F.
        • Verheugt F.W.
        • Lip G.Y.
        Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting.
        Ann Med. 2008; 40: 428-436
        • Rubboli A.
        • Verheugt F.W.
        Antithrombotic treatment for patients on oral anticoagulation undergoing coronary stenting: a review of the available evidence and practical suggestions for the clinician.
        Int J Cardiol. 2008; 123: 234-239